Clinical trials: Bulky Tumors
Diffuse Large B Cell Lymphoma
R-CHOP14 or R-CHOP21 &Consolidation PET-Oriented Radiotherapy (RT) in DLBCL Patients
Prospective, multicentre phase II study with R-CHOP- 14 or R-CHOP-21 \& consolidation PET-oriented radiotherapy (RT) in diffuse large B cell lymphoma (DLBCL) patients
- Trial name
- FIL_DLCL10 (NCT03364439)
- Testing
- Treatment plan
- Where
- 19 sites in Italy
- Volunteers
- 109 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Cancer
Particle-based Partial Tumor Irradiation of Unresectable Bulky Tumors
This study uses a novel, recently developed unconventional radiotherapy technique which consists of three high-dose fractions directed to special segments of unresectable bulky tumors.
- Trial name
- PARTICLE-PATHY (NCT04875871)
- Testing
- Particle radiotherapy, Magnetic resonance imaging, Computertomography
- Where
- Austria
- Volunteers
- 13 people
- Sponsor
- EBG MedAustron GmbH
Cervical Cancer, Neoadjuvant Chemotherapy
Neoadjuvant Chemotherapy Followed by Chemoradiation Versus Chemoradiation for Stage IIIC Cervical Cancer Patients: A Randomized Phase III Trial
Evaluate the efficacy and safety of neoadjuvant chemotherapy (NAC) with albumin-bound paclitaxel and carboplatin followed by chemoradiation therapy (CRT) for stage IIIC cervical cancer patients with carcinoma >4 cm in greatest…
- Conditions
- Cervical Cancer, Neoadjuvant Chemotherapy, Bulky Neoplasm
- Trial name
- N6C (NCT05367206)
- Testing
- Albumin-Bound Paclitaxel, Carboplatin
- Where
- China
- Volunteers
- 280 people
- Sponsor
- Sun Yat-sen University
Lymphoma
Rituximab in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00112931
- Testing
- rituximab, No treatment
- Where
- 72 sites in Australia, New Zealand and 1 more
- Volunteers
- 462 people
- Sponsor
- University College, London
Bystander Effect, Abscopal Effect
SBRT-based PArtial Tumor Irradiation of HYpoxic Segment
This study uses an unconventional radiotherapy schedule developed at our institute, consisting of a short course high-dose partial irradiation targeting exclusively the hypoxic segment of a bulky tumors, which in our preliminary…
- Conditions
- Bystander Effect, Abscopal Effect, Unresectable Malignant Solid Neoplasm, Bulky Tumors
- Trial name
- SBRT-PATHY (NCT04168320)
- Testing
- SBRT-PATHY (SBRT-based PArtial Tumor irradiation targeting HYpoxic segment)
- Where
- Austria
- Volunteers
- 30 people
- Sponsor
- Klinikum Klagenfurt am Wörthersee
Cervical Neoplasms
A Trial of Neoadjuvant Chemotherapy + Surgery vs. Surgery for Bulky Stage I/II Cervical Cancer
To investigate the clinical benefits of neoadjuvant chemotherapy for bulky stage I/II cervical cancer
- Trial name
- NCT00190528
- Testing
- neoadjuvant chemotherapy + radical hysterectomy, radical hysterectomy
- Where
- Japan
- Volunteers
- 200 people
- Sponsor
- Haruhiko Fukuda
Lymphoma
S0014 Combination Chemotherapy Plus Rituximab and Radiation Therapy in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver…
- Trial name
- NCT00005089
- Testing
- rituximab, cyclophosphamide, doxorubicin hydrochloride
- Where
- 92 sites in United States
- Volunteers
- 71 people
- Sponsor
- SWOG Cancer Research Network
Lymphoma
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, vinblastine, and gemcitabine, work in different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00086801
- Testing
- doxorubicin hydrochloride, gemcitabine hydrochloride, vinblastine
- Where
- 47 sites in United States
- Volunteers
- 104 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Uterine Cervical Cancer
Study of Gemcitabine and Concurrent Radiation Followed by Adjuvant Hysterectomy in Bulky Stage Ib and IIa Cervical Carcinoma
The purpose of this study is first to establish what is the ideal dose of gemcitabine, a chemotherapy agent, when given in combination with radiation.
- Trial name
- NCT00184093
- Testing
- Gemcitabine
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Southern California
Lymphoma
Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan
The goal of the clinical research study is to learn if treatment with a combination of three drugs, Cytoxan (cyclophosphamide), Rituxan (rituximab) and Nipent (pentostatin), will help to control the disease in patients with…
- Trial name
- NCT00496873
- Testing
- Cytoxan, Nipent, Rituxan
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Uterine Cervix Cancer
Hypofractionated Radiochemotherapy
The goal of this clinical trial is to investigate the use of hypofractionated radiation (delivery of fewer but larger doses of radiation) with concurrent chemotherapy for women with metastatic of bulky uterine cervix cancer.
- Trial name
- NCT06331468
- Testing
- Cisplatin, intensity modulated radiation therapy (IMRT), high-dose-rate (HDR) brachytherapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Denise Fabian
Hodgkin Lymphoma, Adult
Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma
The standard chemotherapy for Hodgkin lymphoma is called ABVD which is a combination of 4 chemotherapy drugs (doxorubicin, bleomycin, vinblastine, and dacarbazine).
- Trial name
- NCT01578967
- Testing
- Brentuximab vedotin, ABVD
- Where
- 6 sites in United States
- Volunteers
- 41 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Carcinoma Cervix
Study on Early Stage Bulky Cervical Cancers
The aim of this study is to establish the role of neoadjuvant chemotherapy and chemo irradiation in carcinoma cervix and to compare its results with the concurrent chemo irradiation in terms of overall survival, disease free…
- Trial name
- NCT01917695
- Testing
- Chemotherapy, External Beam Radiotherapy, Brachytherapy
- Where
- India
- Volunteers
- 180 people
- Sponsor
- Rajkumar Kottayasamy Seenivasagam
Hodgkin Lymphoma
Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma
Brentuximab is an antibody-drug conjugate (ADC), which is the combination of an antibody (a protein that binds to cells) and a chemotherapy molecule.
- Trial name
- NCT01534078
- Testing
- Brentuximab Vedotin, Adriamycin, vinblastine, and dacarbazine
- Where
- 4 sites in United States
- Volunteers
- 34 people
- Sponsor
- Massachusetts General Hospital
Cancer
Iparomlimab and Tuvonralimab Combined With SFRT and Definitive Chemoradiotherapy in Locoregionally Advanced Bulky HNSCC
Study Objectives 1. Primary Objective: The core aim of this study is to investigate whether the sequential approach of Spatially Fractionated Radiotherapy followed by 3 cycles of induction chemotherapy combined with Iparomlimab…
- Trial name
- NCT07041788
- Testing
- Iparomlimab and Tuvonralimab Injection
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Advanced Bulky Malignancies
Study of Advanced Bulky Malignancies With Spatially Fractioned Radiation Therapy
Expand clinical literature on the use of Grid radiation with conventional external beam therapy. Vast majority of therapy is for palliative care to provide relief from pain, but has also shown a reduction in the size of tumor…
- Trial name
- NCT00765570
- Testing
- Spatially Fractioned Radiation Therapy, Treatment Group 1, Standard radiation
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Summa Health System
Solid Tumor
Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors
This is a 3+3 dose escalation phase I study which aims to evaluate the safety and tolerability of low dose radiotherapy (LDRT) plus concurrent partial Stereotactic Ablative Radiotherapy (SBRT) and Tislelizumab in Patients with…
- Trial name
- NCT06349837
- Testing
- Tislelizumab, Low Dose Radiotherapy, Stereotactic Ablative Radiotherapy
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Sichuan University
Cervical Cancer
Radical Hysterectomy Followed by Tailored Adjuvant Therapy Versus Primary Chemoradiation Therapy in Bulky Early-stage Cervical Cancer (KGOG 1029)
To compare 5-year overall survival between patients who undergo radical hysterectomy followed by tailored adjuvant therapy and patients who receive primary chemoradiation therapy in FIGO stage IB2 and IIA2 cervical cancer
- Trial name
- NCT01680523
- Testing
- Radical hysterectomy, Tailored adjuvant therapy, Primary chemoradiation therapy
- Where
- South Korea
- Volunteers
- 409 people
- Sponsor
- Asan Medical Center
Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC), KRAS G12-mutant NSCLC
Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
The purpose of this first in human (FIH) trial was to characterize the safety and tolerability of the SHP2 inhibitor TNO155 alone and in combination with EGF816 (nazartinib) and identify a recommended dose for future studies in…
- Conditions
- Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC), KRAS G12-mutant NSCLC, Esophageal Squamous Cell Cancer (SCC), Head/Neck SCC
- Trial name
- NCT03114319
- Testing
- TNO155, TNO155 in combination with EGF816 (nazartinib)
- Where
- 18 sites in United States, Canada and 7 more
- Volunteers
- 227 people
- Sponsor
- Novartis Pharmaceuticals
Lymphoma, Large B-Cell, Diffuse
90Y-ibritumomab Tiuxetan Consolidation After 6th R-CHOP Chemotherapy in Patients With Bulky Diffuse Large B Cell Lymphoma
This phase II study is aimed at the clinical efficacy and toxicity of 6th R-CHOP chemotherapy followed by ibritumomab tiuxetan (Zevalin) consolidation in patients with limited-stage, bulky diffuse large B cell lymphoma (DLBCL).
- Trial name
- NCT01157988
- Testing
- ibritumomab tiuxetan (Zevalin)
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Chonnam National University Hospital